Supplementary data

Dual-Catalyzed Boryldifluoroallylation of Alkynes: Efficient

Method for Synthesis of Skipped gem-Difluorodienes

Kai-Feng Zhuo, Wen-Yan Xu, Tian-Jun Gong* and Yao Fu*

1. General Information	S2
2. Preparation of Starting Materials	S3
3. General Experimental Procedures	S22
4. References	S132

1. General Information

1.1.Materials

All solvents were purchased and used without further purification. The following Chemicals were purchased and used as received: CuCl (Acros), LiO'Bu (99%, J&K), KO'Bu (99%, Acros), NaO'Bu (99%, Acros), dry THF (J&K). Alkynes and *gem*-difluoroallyl tert-butyl carbonates were obtained from commercial suppliers or prepared according to standard procedures.

1.2. Analytical Methods

¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded on a Bruker 400 MHz spectrometer at 295 K in CDCl₃ unless otherwise noted. Data for ¹H NMR were reported as follows: chemical shift (δ ppm), multiplicity, coupling constant (Hz), and integration. Data for ¹³C NMR were reported as follows: chemical shift (δ ppm), multiplicity, and coupling constant (Hz). Data for ¹⁹F NMR were reported as follows: chemical shift (δ ppm), multiplicity, coupling constant (Hz). Chemical shifts were reported using the residual solvent CHCl₃ as the internal reference for ¹H NMR (δ =7.260 ppm) and CDCl₃ peak as the internal reference for ¹³C NMR (δ = 77.16 ppm). Gas chromatographic (GC) analysis was acquired on a Shimadzu GC-2010 plus Series GC system equipped with a flameionization detector. Organic solutions were concentrated under reduced pressure on Buchi rotary evaporator. Column chromatographic purification of products was accomplished using forced-flow chromatography on Silica Gel (300-400 mesh).



2. Preparation of gem-difluoroallyl tert-butyl carbonate

To a Schlenk tube equipped with a magnetic stir bar were added NaBO₃·4H₂O (3 eq), *gem*-difluoroallylboronates^[1] (10 mmol), THF (10 mL) and H₂O (10 mL). The resulting solution was stirred at room temperature for 20 min. Then Et₂O and water were added and the layers were separated. The aqueous phase was extracted with Et₂O (x 2) and the combined organic layers were dried over Na₂SO₄ and concentrated to give crude product *gem*-difluoroallyl alcohol without any purification.

To a solution of *gem*-difluoroallyl alcohol in CH_2Cl_2 (10 mL) were added ditert-butyl dicarbonate (1.92 g, 15 mmol). Then N,N-dimethylpyridin-4mine(122.2 mg, 1 mmol) was added to the mixture. The resulting solution was stirred at room temperature for 10 min. Then Et_2O and water were added and the layers were separated. The aqueous phase was extracted with Et_2O (x 2) and the combined organic layers were dried over Na_2SO_4 and concentrated. The residue was purified by flash column chromatography on silica gel to give the product.

tert-butyl (3,3-difluoro-2-(4-methoxyphenyl)allyl) carbonate (2a)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as thick oil (1.9 g, 58 %). ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 4.90 (s, 2H), 3.79 (s, 3H), 1.46 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 159.18, 155.51 (dd, J = 296.94, 295.93 Hz), 153.27, 129.40, 123.58, 114.07, 89.12 (dd, J = 18.6, 16.7 Hz), 82.54, 63.03, 55.23, 27.72. ¹⁹F NMR (376 MHz, CDCl₃) δ - 86.14 (d, J = 28.6 Hz), -86.53 (d, J = 28.6 Hz). HRMS (ESI⁺): Calcd for C₁₅H₁₈F₂O₄ [Na]⁺: 323.1071, Found: 323.1074.





tert-butyl (2-(dibenzo[b,d]thiophen-4-yl)-3,3-difluoroallyl) carbonate (2e)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as White solid (2.6 g, 66%). ¹H NMR (400 MHz, CDCl₃) δ 8.20 - 8.06 (m, 2H), 7.96 - 7.70 (m, 1H), 7.61 - 7.43 (m, 3H), 7.41 - 7.37 (m, 1H), 5.00 (s, 1H), 1.40 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.31 (dd, J = 297.3, 294.2 Hz), 153.10, 140.18, 139.12, 136.11, 135.73, 127.97, 127.02, 126.10, 124.80, 124.54, 122.76, 121.79, 121.65 (s), 88.74 (dd, J = 19.19, 20.2Hz), 82.57, 62.43, 27.68. ¹⁹F NMR (377 MHz, CDCl₃) δ -81.50 (d, J = 21.2 Hz), -84.96 (d, J = 21.2 Hz). HRMS (ESI⁺): Calcd for C₂₀H₁₈F₂O₃S [Na]⁺: 399.0842, Found: 399.0847.





ethyl 3-(3-((tert-butoxycarbonyl)oxy)-1,1-difluoroprop-1-en-2-yl)benzoate (2f)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (30:1) as thick oil (2.3 g, 62 %). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.87 (d, *J* = 7.7 Hz, 1H), 7.45 (d, *J* = 7.6 Hz, 1H), 7.36 - 7.29 (m, 1H), 4.85 (d, *J* = 1.7 Hz, 2H), 4.40 - 3.98 (m, 2H), 1.34 (s, 9H), 1.27 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 165.93, 155.70 (dd, *J* = 295.3 Hz), 153.02, 132.46, 131.69, 130.93, 129.25, 128.92, 128.60, 89.22 (dd, *J* = 19.2, 16.3 Hz), 82.45, 62.43, 60.99, 27.52, 14.15 . ¹⁹F NMR (376 MHz, CDCl₃) δ -84.45 (d, *J* = 24.5 Hz), -85.08 (d, *J* = 24.5 Hz). HRMS (ESI⁺): Calcd for C₁₇H₂₀F₂O₅ [H]⁺: 365.1176, Found: 365.1179.





2-(benzo[d][1,3]dioxol-5-yl)-3,3-difluoroallyl tert-butyl carbonate (2g)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as thick oil (2.3 g, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 6.90 - 6.69 (m, 3H), 5.92 (s, 2H), 4.86 (s, 2H), 1.45 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.50 (dd, J = 294.92, 295.93 Hz), 153.13, 147.83, 147.24, 124.92, 121.87, 108.68, 108.33, 101.18, 89.40 (dd, J = 18.8, 16.9 Hz), 82.40, 62.94, 27.58. ¹⁹F NMR (376 MHz, CDCl₃) δ -85.96 (d, J = 28.0 Hz), -86.09 (d, J = 28.0 Hz). HRMS (ESI⁺): Calcd for C₁₅H₁₆F₂O₅ [Na]⁺: 337.0863, Found: 337.0867.





2-([1,1'-biphenyl]-4-yl)-3,3-difluoroallyl tert-butyl carbonate (2h)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as white solid (2.6 g, 69 %). ¹H NMR (400 MHz, CDCl₃) δ 7.63 - 7.55 (m, 4H), 7. 50 - 7.40 (m, 4H), 7.38 - 7.31 (m, 1H), 4.97 (s, 2H), 1.46 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.78 (dd, J = 296.0, 294.7 Hz), 153.24, 140.66, 140.45, 130.37, 128.85, 128.52, 127.53, 127.29, 127.05, 89.37 (dd, J = 18.7, 16.1 Hz), 82.66, 62.78, 27.74. ¹⁹F NMR (376 MHz, CDCl₃) δ -84.30 (d, J = 25.0 Hz), -84.85 (d, J = 25.0 Hz). HRMS (ESI⁺): Calcd for C₂₀H₂₀F₂O₃ [Na]⁺: 369.1278, Found: 369.1256.





tert-butyl (3,3-difluoro-2-(4-(trifluoromethoxy)phenyl)allyl) carbonate (2i)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (2.3 g, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 7.42 (d, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 7.9 Hz, 2H), 4.93 (s, 2H), 1.46 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.72 (dd, *J* = 296.94, 295.93 Hz), 153.09, 148.67 , 130.08, 129.74, 121.47 (q, 257.5 Hz), 121.01, 88.82 (dd, *J* = 19.5, 16.2 Hz), 82.78, 62.53 (d, *J* = 5.0 Hz), 27.62. ¹⁹F NMR (376 MHz, CDCl₃) δ -57.93 (s), -84.12 (d, *J* = 24.2 Hz), -84.79 (d, *J* = 24.2 Hz). HRMS (ESI⁺): Calcd for C₁₅H₁₅F₅O₄ [Na]⁺: 377.0788, Found: 377.0796.





tert-butyl (3,3-difluoro-2-(4-fluorophenyl)allyl) carbonate (2j)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (1.9 g, 61 %). ¹H NMR (400 MHz, CDCl₃) δ 7.38 - 7.32 (m, 2H), 7.10 - 7.02 (m, 2H), 4.91 (s, 2H), 1.46 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 162.24 (d, J = 247.6 Hz), 155.59 (dd, J = 295.93, 294.93 Hz), 153.15, 130.03, 127.32, 115.59 (d, J = 21.7 Hz), 88.89 (dd, J = 19.2, 16.6 Hz), 82.70, 62.77, 27.64. ¹⁹F NMR (376 MHz, CDCl₃) δ -85.16 (d, J = 26.4 Hz), -85.68 (d, J = 26.4 Hz), -113.79 (s). HRMS (ESI⁺): Calcd for C₁₄H₁₅F₃O₃ [Na]⁺: 311.0871, Found: 311.0876.





tert-butyl (3,3-difluoro-2-(4-(trifluoromethyl)phenyl)allyl) carbonate (2k)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (2.3 g, 64 %). ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 8.1 Hz, 2H), 7.51 (d, *J* = 8.0 Hz, 2H), 4.95 (s, 2H), 1.46 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.95 (dd, *J* = 292.1, 288.3 Hz), 153.05, 135.21, 130.34 (q, *J* = 129.98 Hz), 128.53, 125.57, 122.59 , 89.09 (dd, *J* = 19.6, 15.7 Hz), 82.90, 62.31, 27.67. ¹⁹F NMR (376 MHz, CDCl₃) δ -62.81 (s), -82.69 (d, *J* = 21.4 Hz), -83.57 (d, *J* = 21.4 Hz). HRMS (ESI⁺): Calcd for C₁₅H₁₅F₅O₃ [Na]⁺: 361.0839, Found: 361.0842.





tert-butyl (2-(4-chlorophenyl)-3,3-difluoroallyl) carbonate (2l)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (2.2 g, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 7.22 (s, 4H), 4.81 (s, 2H), 1.36 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 155.62 (dd, J = 296.94, 295.93 Hz), 153.09, 133.78, 129.85, 129.49, 128.79, 88.94 (dd, J = 19.3, 16.1 Hz), 82.64, 62.52, 27.62. ¹⁹F NMR (376 MHz, CDCl₃) δ -84.20 (d, J = 24.5 Hz), -84.80 (d, J = 24.5 Hz). HRMS (ESI⁺): Calcd for C₁₄H₁₅ClF₂O₃ [Na]⁺: 327.0575, Found: 327.0593.





3. General Experimental Procedures

3.1 Screening of reaction conditions

In an Ar-filled dry box, Copper source (5 mol%, 0.01 mmol) and lignad were added to a 10 mL Schlenk tube containing a magnetic stirring bar. Then 1 mL dry solvent were added to the mixture, the Schlenk tube was sealed and removed from the dry box and stirred during 15 minutes at r.t. Then B_2pin_2 (1.5 eq, 0.3 mmol) and base (2.0 equiv, 0.4 mmol) were added to the mixture to afford a black suspension. In a separate vial Palladium source (5 mol%, 0.01 mmol), ligand (5 mol%, 0.01 mmol) and 2**a** (1.5 equiv, 0.3 mmol) were stirred in dry solvent (1 mL) for 15 minutes at r.t. **1a** (1 equiv, 0.2 mmol) and this solution and was finally added to the Schlenk tube and heated at 60 °C for 2h. After this time, then reaction was cooled to room temperature. Et_2O and water were added and the layers were separated. The aqueous phase was extracted with Et_2O (x 2) and the combined organic layers were dried over Na_2SO_4 and concentrated. The

residue was purified by flash column chromatography on silica gel to give 3a. The yield and regioselectivity was determined by GC with benzophenone as internal standard.

_

 8	Cu		
	F F	CuCl (5 mol%) /L _{Cu} Pd(dppf)Cl ₂ (5 mol%)	F Bpin F H
ⁿ Bu H +	MeO	NaO ^t Bu (2 eq) B ₂ pin ₂ (1.5 eq) THF, 60 °C, 2 h.	ⁿ Bu
0.2 mmol	2a		OMe
1 equiv	1.5 equiv		3a
Fntry	Cu-L c		NMR Vield(%)
1	Cu-LCu		70 read(70)
1	Dppf (5 mol%)		58
2	Xantphos (5 mol%)		trace
3	Cy-xantphos (5 mol%)		22
4	IMes HCl (5 mol%)		trace
5	PCy₃ (10 mol%)		84
6	$P^{t}Bu_{3}$ (10 mol%)		28
7	PPh_3 (10 mol%)		40
8	/		none

Screening of the $Cu-L_{Cu}$ catalyst seffect on the reactions

Screening of the Pd-L $_{\mbox{Pd}}$ catalyst seffect on the reactions

ⁿ Bu─────H + MeO	F F OBoc	CuCl/PCy ₃ (5 mol%/10 mol% Pd(dba) ₂ /L _{Pd} (5 mol%) NaO ^t Bu (2 eq) B ₂ pin ₂ (1.5 eq) THF, 60 °C, 2 h.) F Bpin F H Bu
0.2 mmol	2a		OMe 3a
1 equiv	1.5 equiv		Ja
Entry	Pd-L _{Pd}		NMR Yield(%)
9	Dppf (5 mol%)		81
10	Dppe	(5 mol%)	trace
11	IMes·H0	Cl (5 mol%)	63
12	PPh ₃	(10mol%)	48
13		/	none

Screening of the Base effect on the reactions

ⁿ Bu─────H + MeO´	F F P OBoc	$\begin{array}{c} PCy_3 (5 \text{ mol}\%/10 \text{ mol}\%) \\ d(dppf)Cl_2 (5 \text{ mol}\%) \\ \hline \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $
0.2 mmol	2a	OMe
1 equiv	1.5 equiv	Sa
Entry	Base	NMR Yield(%)
14	CH ₃ ONa	n 70
15	NaO'Bu	84
16	KO ^t Bu	44
17	LiO ^t Bu	24
18	K_2CO_3	none
19	LiOTMS	trace

Screening of the Solvent effect on the reactions



3.2 General Procedure for the Boryldifluoroallylation of Alkynes

In an Ar-filled dry box, CuCl (5 mol%, 1 mg) and tricyclohexylphosphine (10 mol%, 5.6 mg) were added to a 5 mL Schlenk tube containing a magnetic stirring bar. Then the dry THF (1 mL) were added to the mixture, the Schlenk tube was sealed and removed from the dry box and stirred during 15 minutes at r.t. Then B_2pin_2 (1.5 eq, 0.3 mmol, 76mg) and NaO'Bu (2.0 equiv, 0.4 mmol, 38.4 mg) were added to the mixture to afford a black suspension. In a separate vial Pd(dppf)Cl₂ (5 mol%, 0.001 mmol, 7.1 mg) and tert-butyl (3,3-difluoro-2-

(4-methoxyphenyl)allyl) carbonate **2a** (1.5 equiv, 0.3 mmol, 90 mg) were stirred in dry THF (1 mL) for 15 minutes at r.t. The hex-1-yne **1a** (1 equiv, 0.2 mmol, 16 mg) and this solution and was finally added to the Schlenk tube and heated at 60 °C for 2h. After this time, then reaction was cooled to room temperature. Et₂O and water were added and the layers were separated. The aqueous phase was extracted with Et₂O (x 2) and the combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel to give **3a**.



(Z)-2-(2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)hex-1-en-1-yl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (3a)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as thick oil (66 mg, 84 %). ¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, *J* = 7.8 Hz, 2H), 6.73 (d, *J* = 8.9 Hz, 2H), 5.08 (s, 1H), 3.70 (s, 3H), 3.53 (s, 2H), 1.91 (t, *J* = 7.5 Hz, 2H), 1.36 - 1.20 (m, 4H), 1.18 (s, 12H), 0.78 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.57, 158.57, 154.06 (dd, *J* = 289.4, 286.2 Hz), 129.77, 125.46, 115.70, 113.47, 90.73 (dd, *J* = 21.0, 13.6 Hz), 82.75, 55.16, 37.25, 32.29, 29.67, 24.84, 22.39, 13.90. ¹⁹F NMR (376 MHz, CDCl₃) δ -92.13 (d, *J* = 44.8 Hz), -92.47 (d, *J* = 44.8 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.96. HRMS (ESI⁺): Calcd for C₂₂H₃₁BF₂O₃ [H]⁺: 393.2413, Found: 393.2419.







(E)-2-(2-cyclohexyl-5,5-difluoro-4-(4-methoxyphenyl)penta-1,4-dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3b)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (66 mg, 79 %). ¹H NMR (400 MHz, CDCl₃) δ 7.39 - 7.10 (m, 2H), 6.91 - 6.68 (m, 2H), 5.15 (s, 1H), 3.77 (s, 3H), 3.62 (s, 2H), 1.95 - 1.76 (m, 1H), 1.78 - 1.53 (m, 5H), 1.25 (s, 12H), 1.23 - 0.88 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 167.64, 158.52, 154.19 (dd, *J* = 289.0, 286.2 Hz), 129.90, 125.60, 114.40, 113.41, 90.93 (dd, *J* = 21.0, 13.6 Hz), 82.75, 55.17, 43.88, 32.71, 32.24, 26.88, 26.37, 24.86. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.99 (d, *J* = 44.7 Hz), -92.75 (d, *J* = 44.7 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.15. HRMS (ESI⁺): Calcd for C₂₄H₃₃BF₂O₃ [H]⁺: 419.2569, Found: 419.2571.





(*E*)-2-(2-cyclopropyl-5,5-difluoro-4-(4-methoxyphenyl)penta-1,4-dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3c)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (33.2 mg, 44 %). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.33 - 7.27 (m, 2H), 6.84 - 6.77 (m, 2H), 4.80 (s, 1H), 3.78 (s, 3H), 3.71 (t, *J* = 2.3 Hz, 2H), 1.33 - 1.28 (m, 1H), 1.24 (s, 12H), 0.67 - 0.61 (m, 2H), 0.42 - 0.36 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 164.25 (dd, *J* = 2.4 Hz), 158.48, 154.21 (dd, *J* = 289.0, 286.2 Hz), 129.83 (dd, *J* = 3.2 Hz), 125.59 (dd, *J* = 3.5 Hz), 113.71, 113.38, 90.85 (dd, *J* = 21.0, 13.6 Hz), 82.75, 55.18, 33.99, 24.83, 16.94, 8.30. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -92.19 (d, *J* = 44.4 Hz), -92.59 (d, *J* = 44.4). ¹¹B NMR (128 MHz, CDCl₃) δ 29.88. HRMS (ESI⁺): Calcd for C₂₁H₂₇BF₂O₃ [H]⁺: 377.2100, Found: 377.2092.







(Z)-2-(5,5-difluoro-4-(4-methoxyphenyl)-2-methylpenta-1,4-dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3d)

Bpin F CH₃ PMP

Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (61 mg, 86 %). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.15 (s, 1H), 3.78 (s, 3H), 3.58 (s, 2H), 1.75 (s, 3H), 1.25 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 158.82, 158.56, 154.08 (dd, J = 289.4, 286.5 Hz), 129.65, 125.37, 116.87, 113.51, 90.54 (dd, J = 20.5, 14.1 Hz), 82.77, 55.19, 33.54, 25.34, 24.84. ¹⁹F NMR (376 MHz, CDCl₃) δ -92.12 (d, J = 44.3 Hz), -92.32 (d, J = 44.3 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.58. HRMS (ESI⁺): Calcd for C₁₉H₂₅BF₂O₃ [H]⁺: 351.1943, Found: 351.1948.





(E)-(5,5-difluoro-4-(4-methoxyphenyl)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)penta-1,4-dien-2-yl)triethylsilane (3e)

Bpin TES PMP

Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (45 mg, 50 %). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, *J* = 7.6 Hz, 2H), 6.80 (d, *J* = 8.8 Hz, 2H), 5.84 (s, 1H), 3.78 (s, 3H), 3.71 (s, 2H), 1.28 (s, 12H), 0.78 (t, *J* = 7.8 Hz, 9H), 0.54 (q, *J* = 7.8 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 164.27, 158.39, 153.21 (dd, *J* = 289.6, 286.8 Hz), 130.12, 125.50, 113.73, 113.28, 91.36 (dd, *J* = 20.0, 12.3 Hz), 83.03, 55.19, 33.05, 24.90, 7.26, 2.99. ¹⁹F NMR (376 MHz, CDCl₃) δ -90.31 (d, *J* = 43.4 Hz), -91.52 (d, *J* = 43.4 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 28.80. HRMS (ESI⁺): Calcd for C₂₄H₃₇BF₂O₃Si [H]⁺: 451.2651, Found: 451.2647.






(E)-2-(2-(tert-butyl)-5,5-difluoro-4-(4-methoxyphenyl)penta-1,4-dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3f)

Bpin F F tBu PMP

Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (36 mg, 45 %). ¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, *J* = 8.6 Hz, 2H), 6.75 (d, *J* = 8.4 Hz, 2H), 5.33 (s, 1H), 3.71 (s, 3H), 3.53 (s, 2H), 1.16 (s, 12H), 0.98 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 168.20, 158.56, 152.83 (dd, *J* = 288.8 Hz), 130.52, 125.97, 113.73, 113.31, 92.36 (dd, *J* = 19.8, 16.1 Hz), 82.81, 55.17, 38.56, 30.55, 30.01, 24.85. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.51. ¹¹B NMR (128 MHz, CDCl₃) δ 30.31. HRMS (ESI⁺): Calcd for C₂₂H₃₁BF₂O₃ [H]⁺: 393.2413, Found: 393.2409.





(E)-2-(2-(cyclohex-1-en-1-yl)-5,5-difluoro-4-(4-methoxyphenyl)penta-1,4dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3g)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as thick oil (45 mg, 54 %). ¹H NMR (400 MHz, CDCl₃) δ 7.03 (d, J = 8.6 Hz, 2H), 6.69 (d, J = 8.6 Hz, 2H), 5.80 (s, 1H), 5.17 (s, 1H), 3.70 (s, 2H), 3.69 (s, 3H), 2.02 (s,2H), 1.86 (s, 2H), 1.54 - 1.41 (m, 4H), 1.18 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 159.75 , 158.49, 153.10 (dd, J = 287.8,286.8 Hz), 137.75, 130.30, 127.18, 125.60, 114.56, 113.16, 92.04 (dd, J = 19.8, 16.1 Hz), 82.82, 55.15, 30.09, 26.59, 25.98, 24.82, 22.96, 22.08. ¹⁹F NMR (376 MHz, CDCl₃) δ -93.50 (d, J = 47.1 Hz), -93.67 (d, J = 47.1 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.83. HRMS (ESI⁺): Calcd for C₂₁H₃₁BF₂O₃ [H]⁺: 417.2413, Found: 417.2404.







tert-butyl (E)-4-(5,5-difluoro-4-(4-methoxyphenyl)-1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)penta-1,4-dien-2-yl)piperidine-1-carboxylate (3h) Bpin F



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (10:1) as white solid (71.8 mg, 69 %). ¹H NMR (400 MHz, CDCl₃) δ 7.25 (d, J = 8.0 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.15 (s, 1H), 4.20 - 4.00 (m, 2H), 3.78 (s, 3H), 3.65 (s, 2H), 2.64 - 2.54 (m, 2H), 2.02 - 1.92 (m, 1H), 1.56 - 1.48 (m, 2H), 1.44 (s, 9H), 1.34 - 1.20 (m, 14 H). ¹³C NMR (101 MHz, CDCl₃) δ 164.95, 158.63, 154.82, 154.15 (dd, *J* = 289.6, 286.3 Hz), 129.82, 125.25, 113.67, 113.53, 90.71 (dd, *J* = 20.9, 13.6 Hz), 82.95, 79.33, 55.19, 44.39, 41.96, 31.97, 31.43, 28.45, 24.85. ¹⁹F NMR (376 MHz, CDCl₃) δ - 91.52 (d, *J* = 44.2 Hz), -92.27 (d, *J* = 44.2 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.60. HRMS (ESI⁺): Calcd for C₂₈H₄₀BF₂NO₅ [H]⁺: 520.3046, Found: 520.3057.





(Z)-2-(2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)-6-(naphthalen-2vlmethoxy)hex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3i)

Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (15:1) as thick oil (70.3 mg, 64 %). ¹H NMR (400 MHz, CDCl₃) δ 7.78 - 7.73 (m, 3H), 7.69 (s, 1H), 7.41 - 7.36 (m, 3H), 7.20 (d, J = 7.7 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 5.09 (s, 1H), 4.57 (d, J =7.4 Hz, 2H), 3.68 (s, 3H), 3.53 (s, 2H), 3.40 (t, J = 6.2 Hz, 2H), 1.94 (t, J = 7.2Hz, 2H), 1.57 - 1.48 (m, 2H), 1.46 - 1.38 (m, 2H), 1.18 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 162.02, 158.55, 152.27 (dd, J = 295.5, 288.8 Hz), 136.16, 133.32, 132.95, 129.75, 128.11, 127.89, 127.68, 126.24, 126.00, 125.75, 125.73, 125.36, 116.06, 113.48, 90.68 (dd, J = 21.0, 13.6 Hz), 82.80, 72.99, 70.30, 55.17, 37.27, 32.24, 29.38, 24.86, 24.03. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.96 (d, J = 44.5 Hz), -92.29 (d, J = 44.5 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.02. HRMS (ESI⁺): Calcd for C₃₃H₃₉BF₂O₄ [H]⁺: 549.2988, Found: 549.2990.







(Z)-2-(6-chloro-2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)hex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3j)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as thick oil (61.2 mg, 74 %). ¹H NMR (400 MHz, CDCl₃) δ 7.35 - 7.06 (m, 2H), 6.84 - 6.52 (m, 2H), 5.10 (s, 1H), 3.71 (s, 3H), 3.55 (s, 2H), 3.38 (t, *J* = 6.6 Hz, 2H), 2.07 (t, *J* = 7.5 Hz, 2H), 1.91 - 1.66 (m, 2H), 1.19 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 160.33, 158.63, 154.08 (dd, *J* = 289.9, 286.3 Hz), 129.75, 125.10, 116.67, 113.54, 90.47 (dd, *J* = 21.0, 13.8 Hz), 82.95, 55.20, 44.49, 34.46, 32.28, 30.27, 29.72, 24.86. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.69 (d, *J* = 44.2 Hz), -92.08 (d, *J* = 44.2 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.72. HRMS (ESI⁺): Calcd for C₂₂H₃₀BClF₂O₃ [H]⁺: 427.2023, Found: 427.2069.





(Z)-2-(8,8-difluoro-7-(4-methoxyphenyl)-5-((4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)methylene)oct-7-en-1-yl)isoindoline-1,3-dione (3k) Bpin F



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (10:1) as white solid (65 mg, 60 %). ¹H NMR (400 MHz, CDCl₃) δ 7.86 - 7.81 (m, 2H), 7.73 - 7.67 (m, 2H), 7.37 - 7.23 (m, 2H), 6.84 - 6.70 (m, 2H), 5.14 (s, 1H), 3.77 (s, 3H), 3.64 (t, *J* = 7.1 Hz, 2H), 3.58 (s, 2H), 2.09 - 1.93 (m, 2H), 1.67 - 1.57 (m, 2H), 1.49 - 1.37 (m, 2H), 1.25 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 168.43, 161.56, 158.57, 154.01 (dd, *J* = 289.7, 286.3 Hz), 133.84, 132.14, 129.76, 125.28, 123.18, 113.77, 113.50, 90.61 (dd, *J* = 21.0, 13.6 Hz), 82.84, 55.16, 37.81, 37.07, 32.18, 28.27, 24.84, 24.54. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.90 (d, *J* = 44.5 Hz), -92.31 (d, *J* = 44.5 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.94. HRMS (ESI⁺): Calcd for C₃₀H₃₄BF₂NO₅ [H]⁺: 538.2576, Found: 538.2585.







(Z)-2-(2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)hexa-1,5-dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3l)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (65.7 mg, 84 %). ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, *J* = 8.5 Hz, 2H), 6.81 (d, *J* = 8.1 Hz, 2H), 5.94 - 5.48 (m, 1H), 5.17 (s, 1H), 5.05 - 4.79 (m, 2H), 3.78 (s, 3H), 3.61 (s, 2H), 2.17 - 2.04 (m, 4H), 1.26 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 161.40, 158.59, 154.07 (dd, *J* = 289.6, 286.2 Hz), 138.12, 129.76 (t, *J* = 3.2 Hz), 125.33, 114.66, 113.97, 113.50, 90.60 (dd, *J* = 21.1, 13.6 Hz), 82.83, 55.18, 36.83, 32.39, 31.64, 24.85. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.90 (d, *J* = 44.4 Hz), -92.29 (d, *J* = 44.4 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.67. HRMS (ESI⁺): Calcd for C₂₂H₂₉BF₂O₃ [H]⁺: 391.2256, Found: 391.2260.





(Z)-2-(2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)dec-1-en-5-yn-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3m)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (76.6 mg, 86 %). ¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, *J* = 8.9 Hz, 2H), 6.74 (d, *J* = 8.1 Hz, 2H), 5.09 (s, 1H), 3.71 (s, 3H), 3.54 (s, 2H), 2.21 - 2.08 (m, 4H), 2.05 (t, *J* = 6.4 Hz, 2H), 1.42 - 1.24 (m, 4H), 1.18 (s, 12H), 0.83 (t, *J* = 6.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 160.30, 158.60, 154.07 (dd, *J* = 289.7, 286.9 Hz), 129.78, 125.23, 113.89, 113.50, 90.58 (d, *J* = 20.9 Hz), 82.86, 80.77, 79.27, 55.18, 36.87, 32.36, 31.14, 24.84, 21.92, 18.43, 17.25, 13.62. ¹⁹F NMR (376 MHz, CDCl₃) δ - 91.69 (d, *J* = 44.2 Hz), -92.18 (d, *J* = 44.2 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.54. HRMS (ESI⁺): Calcd for C₂₆H₃₅BF₂O₃ [H]⁺: 445.2726, Found: 445.2727.







(Z)-2-(6,6-difluoro-5-(4-methoxyphenyl)-3-((naphthalen-2-ylmethoxy)methyl)hexa-2,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3n)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (20:1) as thick oil (62.6 mg, 60 %). ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, *J* = 7.6 Hz, 3H), 7.68 (s, 1H), 7.45 - 7.35 (m, 3H), 7.12 (d, *J* = 7.9 Hz, 2H), 6.75 - 6.65 (m, 2H), 4.50 (s, 2H), 3.89 (s, 2H), 3.89 (s, 3H), 3.68 (s, 2H), 1.62 (s, 3H), 1.18 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 158.44, 153.92 (dd, *J* = 286.0 62, 289.062 Hz), 146.89, 136.00, 133.30, 132.96, 129.92, 128.02, 127.90, 127.68, 126.40, 125.98, 125.91, 125.83, 125.73, 114.53, 113.41, 90.91 (dd, *J* = 15.3, 13.1 Hz), 83.16, 72.64, 67.50, 55.16, 31.50, 24.82, 16.57. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.69 (s). ¹¹B NMR (128 MHz, CDCl₃) δ 30.47. HRMS (ESI⁺): Calcd for C₃₁H₃₅BF₂O₄ [H]⁺: 521.2675, Found: 521.2701.





(Z)-2-(6,6-difluoro-5-(4-methoxyphenyl)-3-phenylhexa-2,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (30)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (49.6 mg, 58 %). ¹H NMR (400 MHz, CDCl₃) δ 7.28 - 7.17 (m, 3H), 7.12 (d, *J* = 7.9 Hz, 2H), 6.86 (dd, *J* = 6.9, 5.6 Hz, 2H), 6.79 (d, *J* = 8.8 Hz, 2H), 3.88 (s, 2H), 3.79 (s, 3H), 1.48 (s, 3H), 1.32 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 158.38, 156.65, 152.70 (dd, *J* = 219.2, 69.9 Hz), 141.80, 129.94, 127.95, 127.68, 126.45, 125.80, 113.74, 113.31, 90.43 (dd, *J* = 20.8, 13.3 Hz), 83.22, 55.19, 34.53, 24.93, 18.61. ¹⁹F NMR (376 MHz, CDCl₃) δ -92.27 (d, *J* = 43.3 Hz), -93.23 (d, *J* = 43.3 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.85. HRMS (ESI⁺): Calcd for C₂₅H₂₉BF₂O₃ [H]⁺: 427.2256, Found: 427.2265.





(Z)-2-(5,5-difluoro-4-(4-methoxyphenyl)-1,2-diphenylpenta-1,4-dien-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3p)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as white solid (61 mg, 62 %). ¹H NMR (400 MHz, CDCl₃) δ 7.10 (d, *J* = 8.5 Hz, 2H), 7.02 - 6.91 (m, 6H), 6.82 - 6.77 (m, 4H), 6.72 - 6.64 (m, 2H), 3.96 (s, 2H), 3.80 (s, 3H), 1.30 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 158.47, 153.86 (dd, *J* = 288.5, 287.3 Hz), 151.35, 141.62, 140.76, 130.09, 129.66, 129.02, 127.19, 127.14, 126.24, 125.44, 125.21, 113.54, 113.26, 90.33 (dd, *J* = 20.5, 14.4 Hz), 83.64, 55.22, 35.15, 24.80. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.62 (d, *J* = 42.8 Hz), -92.56 (d, *J* = 42.8 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.73. HRMS (ESI⁺): Calcd for C₃₀H₃₁BF₂O₃ [H]⁺: 489.2413, Found: 489.2412.







(8R,9S,13S,14S)-3-(((E)-6,6-difluoro-5-(4-methoxyphenyl)-3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)hex-5-en-1-yl)oxy)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (3q)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (10:1) as white solid (88.7 mg, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.5 Hz, 1H), 6.82 (d, J = 8.7 Hz, 2H), 6.66 (d, J = 8.4 Hz, 1H), 6.59 (s, 1H), 5.23 (s, 1H), 3.98 (t, J = 7.1 Hz, 3H), 3.78 (s, 3H), 3.67 (s, 2H), 2.97 - 2.88 (m, 2H), 2.57 - 2.43 (m, 3H). 2.47 - 2.38 (m, 1H). 2.28 - 2.20 (m,1H). 2.20 - 2.10 (m, 1H). 2.10 - 1.90 (m, 3H). 1.68 - 1.38 (m, 6H). δ 1.27 (s, 12H). 0.91 (s, 3H). ¹³C NMR (101

MHz, CDCl₃) δ 220.96, 158.67, 158.22, 156.80, 154.13 (dd, J = 290.1, 286.8 Hz), 137.69, 132.01, 129.80, 126.29, 125.12, 117.71, 114.40, 113.58, 112.19, 90.49 (dd, J = 20.8, 13.8 Hz), 82.99, 66.23, 55.20, 50.45, 48.03, 44.00, 38.39, 36.62, 35.89, 32.95, 31.61, 29.64, 26.58, 25.94, 24.87, 21.60, 13.87. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.45 (d, J = 43.7 Hz), -91.84 (d, J = 43.7 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.31. HRMS (ESI⁺): Calcd for C₃₈H₄₈BF₂O₅ [H]⁺: 633.3563, Found: 633.3574.









(E)-2-(3-(3,3-difluoro-2-phenylallyl)hept-2-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4a)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (50 mg, 69 %). ¹H NMR (400 MHz, CDCl₃) δ 7.30 - 7.26 (m, 2H), 7.23 - 7.13 (m, 3H), 5.08 (s, 1H), 3.57 (s, 2H),1.92 (t, *J* = 7.5 Hz, 2H), 1.43 - 1.30 (m, 4H), 1.17 (s, 12H), 0.78 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.38, 154.18 (dd, *J* = 290.3, 286.7 Hz), 133.23, 128.67, 127.99, 127.12, 115.27, 91.30 (dd, *J* = 20.8, 13.4 Hz), 82.77, 37.28, 32.20, 29.66, 24.84, 22.39, 13.94. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.23 (d, *J* = 42.2 Hz), -91.55 (d, *J* = 42.2 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.86. HRMS (ESI⁺): Calcd for C₂₁H₂₉BF₂O₂ [H]⁺: 363.2307, Found: 363.2307.







(Z)-2-(2-([1,1'-biphenyl]-4-yl)-3,3-difluoroallyl)hex-1-en-1-yl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (4b)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as white solid (73.7 mg, 84 %). ¹H NMR (400 MHz, CDCl₃) δ 7.58 - 7.54 (m, 2H), 7.52 - 7.48 (m, 2H), 7.46 – 7.39 (m, 4H), 7.35 - 7.29 (m, 1H), 5.19 (s, 1H), 3.67 (s, 2H), 2.03(t, *J* = 7.5 Hz, 2H), 1.47 - 1.28 (m, 4H), 1.26 (s, 12H), 0.86 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.36, 154.29 (dd, *J* = 290.8, 287.1 Hz), 140.78, 139.91, 132.27, 129.03, 128.74, 127.28, 127.02, 126.73, 115.63, 91.04 (dd, *J* = 21.1, 13.1 Hz), 82.81, 37.31, 32.20, 29.72, 24.86, 22.41, 13.92. ¹⁹F NMR (376 MHz, CDCl₃) δ -90.59 (d, *J* = 41.5 Hz), -90.94 (d, *J* = 41.5 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.77. HRMS (ESI⁺): Calcd for C₂₇H₃₃BF₂O₂ [H]⁺: 439.2620, Found: 439.2632.




(Z)-2-(2-(3,3-difluoro-2-(4-(trifluoromethoxy)phenyl)allyl)hex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4c)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (60 mg, 67 %). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 8.5 Hz,2H), 7.12 (d, *J* = 8.3 Hz, 2H), 5.18 (s, 1H), 3.61 (s, 2H), 1.99 (t, *J* = 7.5 Hz, 2H), 1.43 - 1.33 (m, 4H), 1.23 (s, 12H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 161.85, 154.26 (dd, *J* = 291.0, 287.4 Hz), 148.14, 130.17, 120.45, 119.16(q, *J* = 257.5 Hz), 116.05, 90.41 (dd, *J* = 22.0, 13.4 Hz), 82.83, 37.22, 32.18, 29.65, 24.79, 22.37, 13.91. ¹⁹F NMR (376 MHz, CDCl₃) δ -57.85, -90.47 (d, *J* = 40.8 Hz), -90.83 (d, *J* = 40.8 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 28.95. HRMS (ESI⁺): Calcd for C₂₂H₂₈BF₅O₃ [H]⁺: 447.2130, Found: 447.2115.







ethyl (Z)-3-(1,1-difluoro-4-((3,3,4,4-tetramethyl-113,2,5-bromadioxolan-1-yl)methylene)oct-1-en-2-yl)benzoate (4d)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (30:1) as thick oil (54.8 mg, 63 %). ¹H NMR (400 MHz, CDCl₃) δ 7.98 (s, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 5.16 (s, 1H), 4.36 (q, J = 7.1 Hz, 2H), 3.64 (s, 2H), 2.03 – 1.98 (t, J = 7.5 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H), 1.29 - 1.23 (m, 4H), 1.22 (s, 12H), 0.86 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 166.37, 161.84, 154.28 (dd, J = 290.7, 287.6 Hz), 133.76, 133.09, 130.51, 129.95, 128.34, 128.00, 115.92, 90.83 (dd, J = 21.9, 13.5 Hz), 82.79, 60.98, 37.30, 32.35, 29.65, 24.78, 22.36, 14.33, 13.92. ¹⁹F NMR (376 MHz, CDCl₃) δ - 90.45 (d, J = 40.4 Hz), -90.92 (d, J = 40.4 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.47 . HRMS (ESI⁺): Calcd for C₂₄H₃₃BF₂O₄ [H]⁺: 435.2518, Found: 435.2519.





(Z)-2-(2-(3,3-difluoro-2-(4-(trifluoromethyl)phenyl)allyl)hex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4e)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (51.7 mg, 60 %). ¹H NMR (400 MHz, CDCl₃) δ 7.54 - 7.45 (m, 4H), 5.18 (s, 1H), 3.65 (s, 2H), 2.00 - 1.95 (t, *J* = 7.6 Hz, 2H), 1.45 - 1.29 (m, 4H), 1.24 (s, 12H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 161.58, 154.45 (dd, *J* = 292.1, 288.3 Hz), 137.09 (s), 129.07, 128.62 (q, *J* = 155.54 Hz), 124.95, 116.21, 90.76 (dd, *J* = 21.9, 12.9 Hz), 82.90, 37.26, 32.03, 29.66, 24.83, 22.38, 13.90. ¹⁹F NMR (377 MHz, CDCl₃) δ -62.66, -89.41 (d, *J* = 38.4 Hz), -89.71 (d, *J* = 38.4 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.12. HRMS (ESI⁺): Calcd for C₂₂H₂₈BF₅O₂ [H]⁺: 431.2181, Found: 431.2177.







(Z)-2-(2-(3,3-difluoro-2-(4-fluorophenyl)allyl)hex-1-en-1-yl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (4f)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (64.8 mg, 85 %). ¹H NMR (400 MHz, CDCl₃) δ 7.36 - 7.30 (m, 2H), 7.00 - 6.93 (m, 2H), 5.16 (s, 1H), 3.61 (s, 2H), 1.98 (t, *J* = 7.5Hz, 2H), 1.43 - 1.32 (m, 4H), 1.25 (s, 12H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.09 (s), 161.82 (d, *J* = 246.4 Hz), 154.15 (dd, *J* = 289.9, 287.8 Hz), 130.40 (s), 129.06 (s), 115.83 (s), 114.94 (d, *J* = 21.4 Hz), 90.52 (dd, *J* = 21.6, 13.5 Hz), 82.81 (s), 37.23 (s), 32.24 (s), 29.63 (s), 24.83 (s), 22.38 (s), 13.92 (s). ¹⁹F NMR (376 MHz, CDCl₃) δ - 91.33 (d, *J* = 42.7 Hz), -91.69 (d, *J* = 42.7 Hz), -115.02. ¹¹B NMR (128 MHz, CDCl₃) δ 29.59. HRMS (ESI⁺): Calcd for C₂₁H₂₈BF₃O₂ [H]⁺: 381.2213, Found: 381.2213.





(Z)-2-(2-(2-(4-chlorophenyl)-3,3-difluoroallyl)hex-1-en-1-yl)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (4g)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (59.5 mg, 75 %). ¹H NMR (400 MHz, CDCl₃) δ 7.45 - 6.98 (m, 4H), 5.16 (s, 1H), 3.61 (s, 2H), 1.99 - 1.92 (t, *J* = 7.5 Hz, 2H), 1.46 - 1.30 (m, 4H), 1.26 (s, 12H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 161.96, 154.16 (dd, *J* = 290.3, 286.5 Hz), 132.94, 131.65, 130.02, 128.21, 116.16, 90.54 (dd, *J* = 21.8, 13.1 Hz), 82.85, 37.22, 32.01, 29.61, 24.85, 22.37, 13.93. ¹⁹F NMR (376 MHz, CDCl₃) δ - 90.40 (d, *J* = 40.8 Hz), -90.77 (d, *J* = 40.8 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.25. HRMS (ESI⁺): Calcd for C₂₁H₂₈BClF₂O₂ [H]⁺: 397.1917, Found: 397.1906.





(Z)-2-(2-(2-(benzo[d][1,3]dioxol-5-yl)-3,3-difluoroallyl)hex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4h)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (30:1) as thick oil (48.8 mg, 60 %). ¹H NMR (400 MHz, CDCl₃) δ 6.89 (s, 1H), 6.82 (d, *J* = 8.1 Hz, 1H), 6.72 (d, *J* = 8.1 Hz, 1H), 5.91 (s, 2H), 5.16 (s, 1H), 3.58 (s, 1H). 1.98 (t, *J* = 7.6 Hz, 2H), 1.43 - 1.30 (m, 4H), 1.26 (s, 12H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.37, 154.10 (dd, *J* = 289.6, 286.1 Hz), 147.36, 146.57, 126.72, 122.32 (t, *J* = 3.3 Hz), 115.69, 109.24, 107.91, 100.97, 91.09 (dd, *J* = 21.7, 13.3 Hz), 82.82, 37.24, 32.28, 29.63, 24.85, 22.40, 13.94. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.55 (d, *J* = 43.8 Hz), -92.20 (d, *J* = 43.8 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.59. HRMS (ESI⁺): Calcd for C₂₂H₂₉BF₂O₄ [H]⁺: 407.2205, Found: 407.2213.







(Z)-2-(2-(2-(dibenzo[b,d]thiophen-4-yl)-3,3-difluoroallyl)hex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4i)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (50:1) as white solid (73 mg, 74%). ¹H NMR (400 MHz, CDCl₃) δ 8.16 - 8.08 (m, 1H), 8.07 - 8.04 (m, 1H), 7.89 - 7.81 (m, 1H), 7.47 - 7.42 (m, 2H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.27 (d, *J* = 1.0 Hz, 1H), 5.11 (s, 1H), 3.67 (s, 2H), 2.16 (t, *J* = 7.6 Hz, 2H), 1.46 - 1.35 (m, 2H), 1.34 - 1.21 (m, 2H), 0.99 (s, 12H), 0.87 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 161.49, 153.62 (dd, *J* = 288.86, 290.88 Hz), 140.22, 139.35, 135.86, 135.70, 128.20, 128.03, 126.73, 124.26, 122.67, 121.58, 120.79, 116.21, 90.37 (dd, *J* = 23.1, 16.1 Hz), 82.53, 37.77, 32.57, 29.83, 24.52, 22.44, 13.95. ¹⁹F NMR (377 MHz, CDCl₃) δ -85.84 (d, *J* = 37.3 Hz), -91.39 (d, *J* = 37.3 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 29.79. HRMS (ESI⁺): Calcd for C₂₇H₃₁BF₂O₂S [Na]⁺: 491.2004, Found: 491.1993.





(Z)-2-(6,6-difluoro-3,5-diphenylhexa-2,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4j)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (44.5 mg, 56 %). ¹H NMR (400 MHz, CDCl₃) δ 7.29 - 6.99 (m, 8H), 6.84 - 6.68 (m, 2H), 3.84 (s, 2H), 1.40 (s, 3H), 1.24 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 153.92 (dd, *J* = 290.2, 287.0 Hz), 152.12, 141.77, 133.60, 128.83, 127.96, 127.86, 127.71,126.88, 126.48, 114.87, 90.99 (dd, *J* = 20.7, 13.1 Hz), 83.23, 34.50, 24.91, 18.61. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.23 (d, *J* = 40.8 Hz), -92.29 (d, *J* = 40.8 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.96. HRMS (ESI⁺): Calcd for C₂₄H₂₇BF₂O₂ [H]⁺: 397.2150, Found: 397.2160.







(Z)-2-(5-([1,1'-biphenyl]-4-yl)-6,6-difluoro-3-phenylhexa-2,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4k)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as white solid (70 mg, 74 %). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, *J* = 7.9 Hz, 2H), 7.44 - 7.31 (m, 4H), 7.27 (t, *J* = 7.0 Hz, 1H), 7.21 - 7.14 (m, 5H), 6.81 (d, *J* = 7.6 Hz, 2H), 3.88 (s, 2H), 1.42 (s, 3H), 1.26 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 154.01 (dd, *J* = 290.6, 287.6 Hz), 152.14, 141.78, 140.81, 139.56, 132.67, 129.16, 128.75, 127.96, 127.74, 127.25, 127.00, 126.55, 126.49, 116.34, 90.73 (dd, *J* = 20.8, 12.9 Hz), 83.26, 34.44, 24.93, 18.61. ¹⁹F NMR (376 MHz, CDCl₃) δ -90.61 (d, *J* = 40.0 Hz), -91.69 (d, *J* = 40.0 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.41. HRMS (ESI⁺): Calcd for C₃₀H₃₁BF₂O₂ [H]⁺: 473.2463, Found: 473.2466.





(Z)-2-(6,6-difluoro-5-(4-fluorophenyl)-3-phenylhexa-2,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4l)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (56.4 g, 68 %). ¹H NMR (400 MHz, CDCl₃) δ 7.29 - 7.11 (m, 5H), 6.98 – 6.89 (m, 2H), 6.84 (d, J = 6.9 Hz, 2H), 3.90 (s, 2H), 1.49 (s, 3H), 1.31 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 161.70 (d, J = 246.1 Hz), 153.89 (dd, J = 290.0, 287.6 Hz), 151.87, 141.62, 130.46, 129.45, 127.93, 127.76, 126.59, 116.44, 114.78 (d, J = 21.4 Hz), 90.31 (dd, J = 21.5, 13.2 Hz), 83.27, 34.49, 24.91, 18.62. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.34 (d, J = 41.3 Hz), -92.46 (d, J = 41.3 Hz), -115.30. ¹¹B NMR (128 MHz, CDCl₃) δ 30.71. HRMS (ESI⁺): Calcd for C₂₄H₂₆BF₃O₂ [H]⁺: 415.2056, Found: 415.2066.







tetramethyl-1,3,2-dioxaborolane (4m)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (51.7 g, 60 %). ¹H NMR (400 MHz, CDCl₃) δ 7.29 - 7.16 (m, 5H), 7.13 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 6.6 Hz, 2H), 3.90 (s, 2H), 1.49 (s, 3H), 1.32 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 153.91 (dd, J = 290.8, 287.7 Hz), 151.74, 141.56, 132.66, 132.04, 130.18, 128.04, 127.89, 127.77, 126.58, 116.14, 90.36 (dd, J = 21.5, 12.8 Hz), 83.28, 34.25, 24.91, 18.58. ¹⁹F NMR (376 MHz, CDCl₃) δ -90.43 (d, J = 39.4 Hz), -91.57 (d, J = 39.4 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.81. HRMS (ESI⁺): Calcd for C₂₄H₂₆BClF₂O₂ [H]⁺: 431.1761, Found: 431.1749.





(Z)-2-(5-(benzo[d][1,3]dioxol-5-yl)-6,6-difluoro-3-phenylhexa-2,5-dien-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4n)



Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (30:1) as thick oil (49.4 mg, 56 %). ¹H NMR (400 MHz, CDCl₃) δ 7.28 - 7.14 (m, 3H), 6.99 - 6.83 (m, 2H), 6.76 - 6.62 (m, 3H), 5.92 (s, 2H), 3.86 (s, 2H), 1.49 (s, 3H), 1.32 (s, 12H). ¹³C NMR (101 MHz, CDCl₃) δ 153.85 (dd, *J* = 289.2, 286.6 Hz), 152.17, 147.24, 146.39, 141.77, 129.43, 127.95, 127.72, 126.52, 122.51, 114.49, 109.41, 107.80, 100.93, 90.78 (dd, *J* = 21.3, 13.2 Hz), 83.26, 34.65, 24.93, 18.65. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.89 (d, *J* = 42.4 Hz), -92.61 (d, *J* = 42.4 Hz). ¹¹B NMR (128 MHz, CDCl₃) δ 30.64. HRMS (ESI⁺): Calcd for C₂₅H₂₇BF₂O₄ [H]⁺: 441.2049, Found: 441.2052.









Following general procedure, The product was isolated by column chromatography with hexane/ethyl acetate (100:1) as thick oil (55.6 mg, 70 %). ¹H NMR (400 MHz, CDCl₃) δ 7.39 - 7.26 (m, 2H), 6.97 - 6.87 (m, 2H), 5.85 (s, 1H), 3.71 (s, 2H), 1.22 (s, 12H), 0.00 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 167.77, 164.09, 154.42 (dd, J = 289.5, 288.0 Hz), 131.87, 130.23, 116.02, 115.81, 92.23 (dd, J = 21.1, 12.6 Hz), 84.19, 33.77, 25.96. ¹⁹F NMR (376 MHz, CDCl₃) δ -89.89 (d, J = 41.8 Hz), -90.98 (d, J = 41.8 Hz), -115.22 (s). ¹¹B NMR (128 MHz, CDCl₃) δ 28.48. HRMS (ESI⁺): Calcd for C₂₀H₂₈BF₃O₂Si [H]⁺: 397.1982, Found: 397.1988.





3.3 Gram-scale reaction



In an Ar-filled dry box, CuCl (5 mol%, 49.5 mg) and PCy₃ (10 mol%, 280.4 mg) were added to a 100 mL Schlenk tube containing a magnetic stirring bar. Then the dry THF (30 mL) were added to the mixture, The Schlenk tube was sealed and removed from the dry box and stirred during 15 minutes at r.t. Then $B_2 pin_2$ (1.5 eq, 15 mmol, 3.8 g) and NaO^tBu (2.0 equiv, 20 mmol, 1.9 g) were added to the mixture to afford a black suspension. In a separate vial $Pd(dppf)Cl_2$ (5) mol%, 365.8 mg) and tert-butyl (3,3-difluoro-2-(4methoxyphenyl)allyl) carbonate (1.5 equiv, 15 mmol, 4.5 g) were stirred in dry THF (5 mL) for 15 minutes at r.t. The hex-1-yne (1 equiv, 10 mmol, 0.8 g) and This solution and was finally added to the Schlenk tube and heated at 60 °C for 2h. After this time, then reaction was cooled to room temperature. Et₂O and water were added and the layers were separated. The aqueous phase was extracted with Et₂O (x 2) and the combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel to give **3a** (3.1 g, 78 %).



In an Ar-filled dry box, CuCl (5 mol%, 24.7 mg) and PCy₃ (10 mol%, 140 mg) were added to a 100 mL Schlenk tube containing a magnetic stirring bar. Then the dry THF (30 mL) were added to the mixture, The Schlenk tube was

sealed and removed from the dry box and stirred during 15 minutes at r.t. Then B_2pin_2 (1.5 eq, 7.5 mmol, 1.9 g) and NaO^tBu (2.0 equiv, 10 mmol, 0.96 g) were added to the mixture to afford a black suspension. In a separate vial Pd(dppf)Cl₂ (5 mol%, 183 mg) and tert-butyl (3,3-difluoro-2-(4-fluorophenyl)allyl) carbonate (1.5 equiv, 7.5 mmol, 2.2 g) were stirred in dry THF (5 mL) for 15 minutes at r.t. The ethynyltrimethylsilane (1 eq, 5 mmol, 490 mg) and This solution and was finally added to the Schlenk tube and heated at 60 °C for 2h. After this time, then reaction was cooled to room temperature. Et₂O and water were added and the layers were separated. The aqueous phase was extracted with Et₂O (x 2) and the combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel to give **40** (1.4 g, 70 %).

3.4 Experimental Procedures for example described in application:



To the **3a** (0.3 mmol, 117.6 mg, 1.5 eq) product in Pd(PPh₃)₄ (11.55 mg, 0.05 eq), K_3PO_4 (0.6 mmol, 127.2 mg, 3 eq), THF (2 mL) and H_2O (1 mL) was added methyl 5-bromofuran-2-carboxylate (0.2 mmol, 40.78 mg, 1 eq), the resulting mixture was stirred at 80 °C for 8 h. The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate and the combined organic layer was dried over Na₂SO₄. Then the orgnic layer was concentrated and the residue was purified by columnchromatography with hexane/ethyl acetate (30:1) to give **5** as a thick oil (70.2 mg, 90 %).
methyl (Z)-5-(2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)hex-1-en-1-yl)furan-2-carboxylate (5)



¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, J = 8.6 Hz, 2H), 7.14 (d, J = 3.5 Hz, 1H), 6.77 (d, J = 8.7 Hz, 2H), 6.18 (d, J = 3.4 Hz, 1H), 6.09 (s, 1H), 3.90 (s, 3H), 3.75 (s, 3H), 3.67 (s, 2H), 2.06 (t, J = 7.6 Hz, 2H), 1.48 - 1.38 (m, 2H), 1.33 - 1.25 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 159.21, 158.69, 156.40, 154.10 (dd, J = 289.8, 286.9 Hz), 144.02, 142.39, 129.44, 125.18, 119.50, 115.12, 113.67, 110.31, 89.95 (dd, J = 20.8, 14.4 Hz), 55.17, 51.82, 36.15, 30.04, 29.88, 22.38, 13.89. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.08 (d, J = 43.4 Hz), -91.53 (d, J = 43.4 Hz). HRMS (ESI⁺): Calcd for C₂₂H₂₄F₂O₄ [H]⁺: 391.1721, Found: 391.1721.







To the **3a** (0.3 mmol, 117.6 mg, 1.5 eq) product in $Pd(PPh_3)_4$ (11.55 mg, 0.05 eq), K_3PO_4 (0.6 mmol, 127.2 mg, 3 eq), THF (2 mL) and H_2O (1 mL) was added methyl methyl 2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate (0.2 mmol, 81 mg, 1 eq), the resulting mixture was stirred at 80 °C for 8 h.The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate, and the combined organic layer was dried over Na₂SO₄. Then the layer concentrated and the residue purified orgnic was was bv columnchromatography with hexane/ethyl acetate (5:1) to give the 6 as a white solid (81.5 mg, 75%).

Methyl (Z)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-(3,3-difluoro-2-(4-methoxyphenyl)allyl)hex-1-en-1-yl)phenyl)propanoate (6)



¹H NMR (400 MHz, CDCl₃) δ 6.98 (d, J = 8.1 Hz, 2H), 6.90 (d, J = 8.2 Hz, 4H), 6.75 - 6.60 (m, 2H), 6.22 (s, 1H), 4.91 (d, J = 7.6 Hz, 1H), 4.62 – 4.55 (q, 1H), 3.71 (s, 3H), 3.64 (s, 3H), 3.24 (s, 2H), 3.07 - 2.86 (m, 2H), 1.96 (t, J = 7.3 Hz, 2H), 1.45 - 1.37 (m, 2H), 1.35 (s, 9H), 1.31 - 1.11 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 172.39, 158.63, 153.86 (dd, J = 289.7, 286.3 Hz), 139.25, 137.61, 136.92, 133.90, 131.33, 129.45, 129.07, 128.96, 126.95, 125.23, 113.57, 90.17 (dd, J = 20.7, 13.5 Hz), 79.96, 55.20, 54.48, 52.19, 38.11, 35.64, 30.16, 28.57, 28.30, 22.45, 13.97. ¹⁹F NMR (377 MHz, CDCl₃) δ -91.42 (d, J = 44.5 Hz), -92.09 (d, J = 44.5 Hz). HRMS (ESI⁺): Calcd for C₃₁H₃₉F₂NO₅ [Na]⁺: 544.2875, Found: 544.2872.





To a solution of **3a** (0.2 mmol, 78.4 mg, 1 eq) in THF (1 mL) were added a solution of NaOH (0.1 mL, 0.3 mmol, 3 M in water). The obtained mixture was stirred for 10 min at 23 °C, followed by dropwise addition of a solution of I_2 (50 mg, 0.2 mmol, 1 eq) in THF (1 mL). After 1 h at 23 °C, the reaction mixture was quenched with brine and extracted with ethyl acetate. The combined organic fraction was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography with hexane to give the **7** as a thick oil (66.6 mg, 85%).

(Z)-1-(1,1-difluoro-4-(iodomethylene)oct-1-en-2-yl)-4-methoxybenzene (7)



¹H NMR (400 MHz, CDCl₃) δ 7.24 (d, *J* = 7.4 Hz, 2H), 6.86 (d, *J* = 8.5 Hz, 2H), 5.95 (s, 1H), 3.80 (s, 3H), 3.35 (s, 2H), 2.04 (t, *J* = 7.5 Hz, 2H), 1.42 - 1.30 (m, 2H), 1.28 - 1.18 (m, 2H), 0.86 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.83, 154.12 (dd, *J* = 289.5, 288.2 Hz), 147.97, 129.53, 124.76, 113.74, 89.60 (dd, *J* = 19.2, 16.2 Hz), 77.15, 55.21, 35.99, 35.32, 29.65, 22.19, 13.78. ¹⁹F NMR (376 MHz, CDCl₃) δ -90.79 (d, *J* = 42.5 Hz), -90.92 (d, *J* = 42.5 Hz). HRMS (ESI⁺): Calcd for C₁₆H₁₉F₃IO [H]⁺: 393.0527, Found: 393.0510.







To the 7 (0.1 mmol, 39.2 mg, 1 eq) product in Pd(PPh₃)₄ (11.55 mg, 0.1 eq) and THF (2 mL) and H₂O (1 mL) was added K₃PO₄(0.3 mmol, 63.6 mg, 3 eq) and alkenyl boronates (0.2 mmol, 48.3 mg, 2 eq). The resulting mixture was stirred at 80 °C for 8 h. The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate and the combined organic layer was dried over Na₂SO₄. Then the orgnic layer was concentrated and The residue was purified by columnchromatography with hexane to give **8** as a thick oil (25.6 mg, 67 %).

1-((Z)-1,1-difluoro-4-((E)-2-methyl-3-phenylallylidene)oct-1-en-2-yl)-4methoxybenzene (8)



¹H NMR (400 MHz, CDCl₃) δ 7.30 - 7.24 (m, 3H), 7.18 - 7.05 (m, 4H), 6.77 (d, J = 8.8 Hz, 2H), 6.09 (s, 1H), 5.72 (s, 1H), 3.73 (s, 3H), 3.35 (s, 2H), 2.05 (t, J = 7.6 Hz, 2H), 1.70 (s, 3H), 1.45 - 1.31 (m, 2H), 1.30 - 1.15 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.66, 154.04 (dd, J = 280.3, 278.2 Hz), 137.98, 137.30, 135.26, 131.71, 129.59, 128.96, 128.30, 128.11, 126.25, 113.65, 90.52 (dd, J = 13.3, 8.3 Hz), 55.24, 35.60, 30.25, 28.76, 22.48, 18.85, 13.99. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.89 (d, J = 45.0 Hz), -92.54 (d, J = 45.0 Hz). HRMS (ESI⁺): Calcd for C₂₅H₂₈F₂O [Na]⁺: 405.2006, Found: 405.2020.





According to the reported literature^[2], **9** were conveniently synthesized under slightly modified reaction conditions. To the **3a** (0.2 mmol, 78.4 mg, 1 eq) product in Pd(PPh₃)₄ (11.6 mg, 0.05 eq) and THF (2 mL) and H₂O (1 mL) was added K₃PO₄ (0.6 mmol,127.2 mg, 3 eq) and 3-bromo-3,3-difluoroprop-1-ene (0.3 mmol, 46.8 mg, 1.5 eq). The resulting mixture was stirred at 80 °C for 8 h. The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate and the combined organic layer was dried over Na₂SO₄. Then the The residue orgnic layer concentrated and was purified by was columnchromatography with hexane to give the 9 as a thick oil (41 mg, 60%).

(Z)-1-(4-butyl-1,1,6,6-tetrafluoroocta-1,4,7-trien-2-yl)-4-methoxybenzene (9)



¹H NMR (400 MHz, CDCl₃) δ 7.13 (d, J = 8.9 Hz, 2H), 6.79 (d, J = 8.9 Hz, 2H), 5.88 - 5.73 (m, 1H), 5.50 - 5.40 (m, 1H), 5.37 - 5.30 (m, 1H), 5.29 - 5.25 (m, 1H), 3.73 (s, 3H), 3.29 (s, 2H), 1.89 (t, J = 7.2 Hz, 2H), 1.36 - 1.25 (m, 2H), 1.23 - 1.15 (m, 2H), 0.81 (t, J = 7.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.83, 154.13 (dd, J = 289.4, 287.1 Hz), 146.54, 133.49, 129.65, 125.11, 121.31, 119.08, 118.68, 113.73, 89.56 (dd, J = 20.4, 14.8 Hz), 55.22, 35.42, 29.76, 29.17, 22.32, 13.85. ¹⁹F NMR (376 MHz, CDCl₃) δ -86.99 (s), -90.94 (d, J = 42.7 Hz), -91.04 (d, J = 42.7 Hz). HRMS (ESI⁺): Calcd for C₂₄H₂₆BF₃O₂ [H]⁺: 343.1685, Found: 343.1689.







Oxidation of **3o** were performed accoding to the literature^[3]. To the **3o** (0.2 mmol, 85.2 mg, 1 eq) product in THF (2 mL) and H₂O (2 mL) was added NaBO₃·4H₂O (0.6 mmol, 92.32 mg, 3 eq). The resulting mixture was stirred at room temperature for 20 min. The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate and the combined organic layer was dried over Na₂SO₄. Then the orgnic layer was concentrated and The residue was purified by columnchromatography with hexane/ethyl acetate (30:1) to give the title compound as a thick oil (51.2 mg, 81 %).

(R)-6,6-difluoro-5-(4-methoxyphenyl)-3-phenylhex-5-en-2-one (10)



¹H NMR (400 MHz, CDCl₃) δ 7.26 - 7.19 (m, 4H), 7.03 - 6.98 (m, 3H), 6.84 - 6.79 (m, 2H), 3.76 (s, 3H), 3.51 - 3.44 (m, 1H), 3.02 - 2.93 (m, 1H), 2.80 - 2.72 (m, 1H), 1.87 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 207.45, 158.83, 153.76 (dd, J = 288.86, 284.86 Hz), 137.64, 129.59, 128.89, 128.40, 127.57, 125.05, 113.98, 89.44 (dd, J = 21.6, 15.7 Hz), 57.06, 55.27, 29.96, 29.00. ¹⁹F NMR (376 MHz, CDCl₃) δ -91.35 (d, J = 42.7 Hz), -91.88 (d, J = 42.7 Hz). HRMS (ESI⁺): Calcd for C₁₉H₁₈F₂O₂ [Na]⁺: 339.1173, Found: 339.1166.







To the **4o** (0.5 mmol, 198.1 mg, 1 eq) product in THF (3 mL) and H₂O (3 mL) was added NaBO₃·4H₂O (1 mmol, 153.8 mg, 2 eq). The resulting mixture was stirred at room temperature for 10 min. The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate, and the combined organic layer was dried over Na₂SO₄. Then the orgnic layer was concentrated and The residue was purified by columnchromatography with hexane/ethyl acetate (30:1) to give the aldehyde as a thick oil (85 %, 91 mg).

5,5-difluoro-4-(4-fluorophenyl)pent-4-enal



¹H NMR (400 MHz, CDCl₃) δ 9.73 (s, 1H), 7.28 - 7.22 (m, 2H), 7.11 - 7.00 (m, 2H), 2.97 - 2.58 (m, 2H), 2.50 (t, *J* = 7.5 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 200.66, 162.07 (d, *J* = 247.6 Hz), 153.43 (dd, *J* = 289.4, 287.7 Hz), 129.99, 128.50, 115.70 (d, *J* = 21.6 Hz), 90.21 (dd, *J* = 21.7, 15.5 Hz), 41.77, 20.63. ¹⁹F NMR (376 MHz, CDCl₃) δ -90.28 (d, *J* = 41.5 Hz), -90.53 (d, *J* = 41.5 Hz), -113.96 (s). HRMS (ESI⁺): Calcd for C₁₁H₉F₃O [H]⁺: 215.0684, Found: 215.0687.







To the solution of the aldehyde (0.2 mmol, 42.8 mg, 1 eq) in THF (1 mL) was added NaBH₄ (0.24 mmol, 9 mg, 1.2 eq). The resulting mixture was stirred at room temperature for 3 min. The resulting mixture was quenched with brine. The mixture was extracted with ethyl acetate and the combined organic layer was dried over Na₂SO₄. Then the orgnic layer was concentrated and The residue was purified by columnchromatography with hexane/ethyl acetate (10:1) to give **11** as a thick oil (90 %, 38.9 mg).

5,5-difluoro-4-(4-fluorophenyl)pent-4-en-1-ol (11)



¹H NMR (400 MHz, CDCl₃) δ 7.27 - 7.16 (m, 2H), 7.04 - 6.91 (m, 2H), 3.56 (t, J = 6.4 Hz, 2H), 2.53 - 2.31 (m, 2H), 1.64 - 1.46 (m, 2H), 1.36 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 161.91 (d, J = 247.0 Hz), 153.58 (dd, J = 290.88, 289.87 Hz), 129.91, 129.38, 115.50 (d, J = 21.6 Hz), 91.11 (dd, J = 19.2, 16.6 Hz), 61.90, 30.59, 24.14. ¹⁹F NMR (377 MHz, CDCl₃) δ -91.39, -114.59. HRMS (ESI⁺): Calcd for C₁₁H₁₁F₃O [Na]⁺: 239.0660, Found: 239.0654.





Proposed reaction mechanism.

We designed the following mechanism experiments to prepare the Pd species, regrettably, we did not get the Pd species, but we obtained the $C(F_2)$ -O cross-coupling by-product in 80% yield.



Then, other 3,3-difluoro-substituted allylic esters (**2b**, **2c**) were used, $C(F_2)$ -O crosscoupling product were observed in 78% and 76% yields, respectively. It's noticed that, the reaction was take place at CF_2 site.



General procedures: To a Schlenk tube equipped with a magnetic stir bar were added Pd_2dba_3 (0.025 mmol), dppf (0.05 mmol), 3,3-difluoro-substituted allylic esters (0.05 mmol) and THF (0.5 mL). The resulting solution was stirred at room temperature for 1 h. Then NaO^tBu (0.05 mmol) was added to the mixture. The resulting solution was stirred at room temperature for 2 h. After this time, then reaction was cooled to room temperature. Et₂O and water were added and the layers were separated. The aqueous phase was extracted with Et₂O (x 2) and the combined organic layers were dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography on silica gel to give the product.

Based on previous work^[4], a proposed mechanism was shown for the formation of the byproduct. $Pd(\eta_3-p-allyl)(X)(dppf)$ was formed firstly, then soft nucleophile -O'Bu directly attacks to η_3 -allyl-Pd species afford the C-O coupling product. The process go through the following mechanism:



However, in the Cu/Pd catalyzed boryldifluoroallylation, C-C bond formation occur at CF₂ site, and this result is contrast with the findings of above mentioned C-O cross-coupling. The difference in reaction mechanism may be the reason for the selectivity of these two sites. A proposed mechanism was shown as follows^[5]: First, regio- and stereoselective borylcupration of the alkyne with LCu-Bpin complex would catalytically generate borylalkenylcopper intermediate. Meanwhile, a π -allyl Pd(II) complex would be formed by oxidative addition of an allyl substrate to a Pd(0) complex. Then, transmetalation between borylalkenylcopper intermediate and Pd(II) complex afford new Pd-complex. Finally, regioselective C-C reductive elimination formation of the product and regeneration of the catalysts.





¹H NMR (400 MHz, CDCl₃) δ 7.49 – 7.30 (m, 2H), 7.22 – 6.72 (m, 2H), 5.87 (s, 1H), 5.64 (s, 1H), 3.82 (s, 3H), 1.41 (s, 9H). ¹⁹F NMR (377 MHz, CDCl₃) δ -69.82 (s). ¹³C NMR (101 MHz, CDCl₃) δ 159.90, 140.31, 129.03, 127.03, 120.83, 118.90, 113.74, 84.72, 55.30, 27.39.





4. References

- [1] Y. Liu, Y. Zhou, Y. Zhao and J. Qu, Org. Lett. 2017, 19, 946-949.
- [2] Q.-Q. Min, Z. Yin, Z. Feng, W.-H. Guo and X. Zhang, J. Am. Chem. Soc. 2014, 136, 1230-1233.
- [3] W. Su, T.-J. Gong, Q. Zhang, Q. Zhang, B. Xiao and Y. Fu, ACS Catal. 2016, 6, 6417-6421.
- [4] T. Rukkijakan, S. Akkarasamiyo, S. Sawadjoon and J. S. M. Samec. J. Org. Chem. 2018, 83, 4099.
- [5] (a) T. Jia, P. Cao, B. Wang, Y. Lou, X. Yin, M. Wang and J. Liao, J. Am. Chem. Soc., 2015, 137,

13760; (b) E. Rivera-Chao and M. Fañanás-Mastral, Angew. Chem., Int. Ed., 2018, 57, 9945.